Carfilzomib, sold under the trade name Kyprolis, is an anticancer drug that can be used as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxy ketone and its analogue cyclooxygenin. Carfilzomib was developed by Onyx Pharmaceuticals. The U.S. Food and Drug Administration (FDA) approved the drug on July 20, 2012 for patients with multiple myeloma. Carfilzomib binds irreversibly to 20S proteasome chymotrypsin, while bortezomib is reversible. In addition, carfilzomib can also inhibit trypsin and hemiacyl aspartase-like enzymes. Irreversible inhibition and selective inhibition give carfilzomib a potential advantage, surpassing bortezomib in terms of efficacy and tolerability.
The basic chemical information of Carfilzomib is as follows:
Molecular weight: 719.9099
Molecular formula: C40H57N5O7
60 mg of carfilzomib in carfilzomib injection is equipped with 3000 mg of sulfobutyl ether beta cyclodextrin sodium (SBECD)
The molar ratio of carfilzomib to betadex sulfobutyl ether sodium SBECD is 1:16.
Shandong Binzhou Zhiyuan Biotechnolody Co., Ltd is a professional manufacturer of cyclodextrin derivatives. Its main products include betadex sulfobutyl ether sodium, methyl beta cyclodextrin (MBCD), hydroxypropyl beta cyclodextrin (HPBCD) pharmaceutical grade, technical grade and daily chemical grade. The produced sulfobutyl ether beta cyclodextrin (SBECD) has been jointly declared with pharmaceutical companies. Methyl beta cyclodextrin (MBCD) has various cyclodextrin reagents for universities and used by scientific research institutions.